UNSPSC 51172812: Benzocaine/clove oil

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR900. This VA Drug Class (OR900) classifies this compound as belonging to the group DENTAL AND ORAL AGENTS, TOPICAL, OTHER.

UNSPSC 51172812 Benzocaine/clove oil is a Commodity code encompassing topical anesthetic and oral care products procured through state and local cooperative purchasing mechanisms. The recent solicitation under this code involves generic pharmaceutical and over-the-counter product distribution agreements that include benzocaine and clove oil formulations among a broader portfolio of pharmaceutical items. State and local governments acquire these products primarily through multistate cooperative purchasing alliances that consolidate demand across participating agencies and jurisdictions, leveraging authorized pharmaceutical wholesalers to distribute inventory to state and local facilities including correctional institutions, health departments, and other government healthcare operations.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026, with proposals due March 26, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products across participating states including Oregon. Vendors must hold current Good Manufacturing Practices certification and Drug Supply Chain Security Act compliance, maintain relationships with at least two of three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and carry $5 million in commercial general liability coverage. The RFP weights price competitiveness at 75 percent of the evaluation, with administrative requirements, EDI capability, and compliance data formatting comprising the remainder. Contract terms run two years for new responders with optional extensions, while incumbent vendors' amendments extend through June 30, 2028. All awarded products must be available in the marketplace by May 15, 2026, with resulting agreements effective July 1, 2026.